Candel Therapeutics Reports Third Quarter 2026 Financial Results and Recent Corporate Highlights
NEEDHAM, Mass., Nov. 12, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve outcomes for patients with cancer, today announced financial results for the third quarter ended September 30, 2026, and provided a corporate update.
Covered in this story
Analyst targets on Candel Therapeutics Inc
- Jefferies: at $8.38 · target $25 by Oct 2027 · Buy via Investing.com
“At” is the closing price nearest the day the target was reported, the price we score it from; it is not an earlier target. Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $CADL yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Candel Therapeutics Inc →Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.